Compounded semaglutide,
delivered everywhere.
Cora Health provides compounded semaglutide via licensed telehealth providers to residents of all 50 US states. $99/month all-inclusive on the annual plan — prepared by Hallandale Pharmacy or VialsRx, both US-licensed 503A compounding pharmacies (PCAB-accredited). Compounded medications are not FDA-approved and are not therapeutically equivalent to Ozempic® or Wegovy®.
Major US metro areas
Cora Health serves the 20 largest US metropolitan areas with dedicated landing pages covering local healthcare context, state pharmacy regulations, neighborhood-level coverage, and metro-specific FAQs.
- New York City New York
- Los Angeles California
- Chicago Illinois
- Dallas-Fort Worth Texas
- Houston Texas
- Washington DC Virginia
- Philadelphia Pennsylvania
- Miami Florida
- Atlanta Georgia
- Boston Massachusetts
- San Francisco Bay Area California
- Phoenix Arizona
- Inland Empire California
- Detroit Michigan
- Seattle Washington
- Minneapolis-St. Paul Minnesota
- Tampa Bay Florida
- San Diego California
- Denver Colorado
- Baltimore Maryland
Find compounded semaglutide in your state
Each state page includes specific availability information, local pricing, FAQs about telehealth GLP-1 in that state, and details on Cora Health's coverage in your area. Click your state below to view the dedicated landing page.
Northeast
South
Midwest
West
About Cora Health's compounded semaglutide program
Cora Health connects patients with board-certified providers (Wasef Health, PC) for personalized GLP-1 weight loss treatment. The Essential Plan provides compounded semaglutide at $99/month on the annual commitment — covering the licensed-provider consultation, the medication, free expedited shipping anywhere in the US, and ongoing provider support. There is no separate membership fee, no per-dose price increase, and no in-person visit required for most patients.
Compounded semaglutide contains the same molecule (semaglutide, a GLP-1 receptor agonist) as brand-name Ozempic and Wegovy, but it is prepared by state-licensed compounding pharmacies rather than the original brand manufacturer. Compounded medications are not FDA-approved and have not been independently trialed. Clinical trial data for FDA-approved semaglutide (such as the 14.9% mean weight loss reported in the STEP 1 trial) reflects studies of the branded product, not compounded versions. Individual results vary.
For a full breakdown of compounded vs brand-name GLP-1 medications, see our complete comparison guide. To learn more about how telehealth GLP-1 prescribing works, see the complete guide to compounded semaglutide.